Guidance on BE Recommendations for Risperidone
Federal Register Notice: FDA is making available a revised draft guidance for industry on generic risperidone injection, entitled Bioequivalence Recommendations for Risperidone. It provides specific guidance on the design of bioequivalence studies to support ANDAs for risperidone injection. To download this guidance, click here. To view this notice, click here.